Vaxcyte, Inc. $PCVX Shares Bought by Jennison Associates LLC

Posted by Stanley Muller on Jul 20th, 2026

Jennison Associates LLC grew its holdings in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 150.6% during the first quarter, HoldingsChannel reports. The firm owned 1,698,011 shares of the company’s stock after acquiring an additional 1,020,458 shares during the period. Jennison Associates LLC’s holdings in Vaxcyte were worth $98,671,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PCVX. Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after buying an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares in the last quarter. Capital Advisors Ltd. LLC acquired a new position in Vaxcyte during the first quarter worth $58,000. Finally, Allworth Financial LP boosted its stake in Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after buying an additional 731 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Vaxcyte

In other news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $57.28, for a total value of $572,800.00. Following the transaction, the chief financial officer owned 104,395 shares of the company’s stock, valued at $5,979,745.60. This represents a 8.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the transaction, the chief operating officer owned 156,760 shares of the company’s stock, valued at approximately $8,830,290.80. This represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 75,448 shares of company stock worth $4,091,197 over the last quarter. 3.30% of the stock is currently owned by company insiders.

Vaxcyte Stock Performance

PCVX stock opened at $56.20 on Monday. The firm has a market cap of $8.12 billion, a PE ratio of -8.17 and a beta of 1.22. The firm’s 50 day moving average price is $52.34 and its 200-day moving average price is $54.28. Vaxcyte, Inc. has a one year low of $29.08 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the prior year, the firm posted ($1.04) earnings per share. Equities research analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PCVX. Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Vaxcyte currently has an average rating of “Hold” and an average price target of $86.00.

Read Our Latest Stock Report on PCVX

Vaxcyte Company Profile

(Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.